Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F23%3A00009684" target="_blank" >RIV/00023884:_____/23:00009684 - isvavai.cz</a>

Výsledek na webu

<a href="https://pubmed.ncbi.nlm.nih.gov/37361617/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/37361617/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.hroo.2023.04.001" target="_blank" >10.1016/j.hroo.2023.04.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale

Popis výsledku v původním jazyce

BACKGROUND Electrographic flow (EGF) mapping enables the dy-namic detection of functional or active atrial fibrillation (AF) sour-ces outside the pulmonary veins (PVs), and the presence or absence of these sources offers a novel framework for classifying and treat-ing persistent AF patients based on the underlying pathophysiology of their AF disease.OBJECTIVE The primary objective of the FLOW-AF trial is to eval-uate the reliability of the EGF algorithm technology (Ablamap soft-ware) to identify AF sources and guide ablation therapy in patients with persistent AF.METHODS The FLOW-AF trial (NCT04473963) is a prospective, multicenter, randomized clinical study in which patients with persistent or long-standing persistent AF who have failed prior PV isolation (PVI) undergo EGF mapping after confirmation of intact PVI. In total, 85 patients will be enrolled and stratified based on the presence or absence of EGF-identified sources. Patients with an EGF-identified source above the predetermined activity threshold of 26.5% will be randomized in a 1:1 fashion to PVI only vs PVI 1 ablation of EGF-identified extra-PV sources of AF.RESULTS The primary safety endpoint is freedom from serious adverse events related to the procedure through 7 days following the randomization procedure; and the primary effectiveness endpoint is the successful elimination of significant sources of exci-tation with the target parameter the activity of the leading source. CONCLUSIONS The FLOW-AF trial is a randomized study designed to evaluate the ability of the EGF mapping algorithm to identify pa-tients with active extra-PV AF sources.

Název v anglickém jazyce

Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale

Popis výsledku anglicky

BACKGROUND Electrographic flow (EGF) mapping enables the dy-namic detection of functional or active atrial fibrillation (AF) sour-ces outside the pulmonary veins (PVs), and the presence or absence of these sources offers a novel framework for classifying and treat-ing persistent AF patients based on the underlying pathophysiology of their AF disease.OBJECTIVE The primary objective of the FLOW-AF trial is to eval-uate the reliability of the EGF algorithm technology (Ablamap soft-ware) to identify AF sources and guide ablation therapy in patients with persistent AF.METHODS The FLOW-AF trial (NCT04473963) is a prospective, multicenter, randomized clinical study in which patients with persistent or long-standing persistent AF who have failed prior PV isolation (PVI) undergo EGF mapping after confirmation of intact PVI. In total, 85 patients will be enrolled and stratified based on the presence or absence of EGF-identified sources. Patients with an EGF-identified source above the predetermined activity threshold of 26.5% will be randomized in a 1:1 fashion to PVI only vs PVI 1 ablation of EGF-identified extra-PV sources of AF.RESULTS The primary safety endpoint is freedom from serious adverse events related to the procedure through 7 days following the randomization procedure; and the primary effectiveness endpoint is the successful elimination of significant sources of exci-tation with the target parameter the activity of the leading source. CONCLUSIONS The FLOW-AF trial is a randomized study designed to evaluate the ability of the EGF mapping algorithm to identify pa-tients with active extra-PV AF sources.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Heart Rhythm O2

ISSN

2666-5018

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

391-400

Kód UT WoS článku

001032622100001

EID výsledku v databázi Scopus

2-s2.0-85162124228